title: Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.
abstract: Aberrant hypermethylation at CpG sites within the CDKN2A gene is associated with silencing and has been proposed as a target for reactivation using both DNA methylation and histone deacetylation inhibitors. This study investigates the role of selecting tumor samples with a silenced as compared to deleted CDKN2A locus when assessing the efficacy of DNA methyltransferase inhibitor, zebularine, combined with the HDAC inhibitor, depsipeptide. Non-small cell lung cancer cell lines with defined CDKN2A status were analyzed by MTS assay to determine the effect of zebularine or zebularine combined with depsipeptide on tumor cell growth. We observed that zebularine treatment resulted in inhibition of cell growth in 11 out of 12 lung cancer cell lines with silenced CDKN2A, but no cell growth inhibition was detected in the 7 lung cancer cell lines tested with deleted CDKN2A (p>0.001). In addition, we found that the combination of 30 microM zebularine and 6 or 7 nM depsipeptide resulted in a synergistic inhibition of cell growth in tumor cells with silenced CDKN2A (p<0.001, CI=0.70 and 0.57, respectively) but not in tumor cells with deleted CDKN2A. In conclusion, tumor cells with methylated CDKN2A are more sensitive to zebularine than cell lines with deleted CDKN2A and the combination of zebularine/depsipeptide results in a synergistic effect on cell growth inhibition that is also linked with the presence of silenced CDKN2A. Thus, combination of DNA methyltransferase and HDAC inhibitors may be a potential treatment for lung cancer patients, but careful selection of patients will be needed to optimize the benefit of this regimen.
authors.affiliation: Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
authors.forename: Min
authors.initials: M
authors.lastname: Chen
authors.forename: Donna
authors.initials: D
authors.lastname: Voeller
authors.forename: Victor E
authors.initials: VE
authors.lastname: Marquez
authors.forename: Frederic J
authors.initials: FJ
authors.lastname: Kaye
authors.forename: Patricia S
authors.initials: PS
authors.lastname: Steeg
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giaccone
authors.forename: Maria
authors.initials: M
authors.lastname: Zajac-Kaye
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D018899:CpG Islands; D003562:Cytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D047630:Depsipeptides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017353:Gene Deletion; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D020868:Gene Silencing; D019942:Genes, p16; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D057285:Precision Medicine; D013997:Time Factors
chemical_list: D047630:Depsipeptides; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D003562:Cytidine; C009131:pyrimidin-2-one beta-ribofuranoside; D015254:DNA Modification Methylases
references.citation: J Biol Chem. 2000 Jan 28;275(4):2727-32
references.pmid: 10644736
references.citation: Blood. 2000 Mar 15;95(6):1942-9
references.pmid: 10706859
references.citation: Mol Cell Biol. 1995 Sep;15(9):5188-95
references.pmid: 7651436
references.citation: Oncogene. 1995 Sep 21;11(6):1211-6
references.pmid: 7566983
references.citation: Clin Cancer Res. 2005 May 15;11(10):3862-8
references.pmid: 15897587
references.citation: Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16090-5
references.pmid: 16243973
references.citation: Biochem Pharmacol. 1979 Apr 15;28(8):1443-4
references.pmid: 87202
references.citation: J Med Chem. 1986 Aug;29(8):1374-80
references.pmid: 3735306
references.citation: Blood. 2004 Mar 1;103(5):1635-40
references.pmid: 14604977
references.citation: Nat Rev Drug Discov. 2006 Jan;5(1):37-50
references.pmid: 16485345
references.citation: Oncogene. 2005 Mar 31;24(14):2386-97
references.pmid: 15735751
references.citation: Blood. 1999 Aug 1;94(3):1113-20
references.pmid: 10419905
references.citation: J Natl Cancer Inst. 2003 Mar 5;95(5):399-409
references.pmid: 12618505
references.citation: Exp Hematol. 2007 Feb;35(2):263-73
references.pmid: 17258075
references.citation: J Natl Cancer Inst. 2002 Apr 3;94(7):504-13
references.pmid: 11929951
references.citation: Pharmacol Ther. 1985;30(3):277-86
references.pmid: 2433702
references.citation: Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11797-801
references.pmid: 7527544
references.citation: Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
references.pmid: 9618505
references.citation: Lung Cancer. 2001 Dec;34 Suppl 4:S111-5
references.pmid: 11742714
references.citation: Cancer Prev Res (Phila). 2008 Sep;1(4):233-40
references.pmid: 19138966
references.citation: J Mol Biol. 1999 Feb 19;286(2):389-401
references.pmid: 9973559
references.citation: Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
references.pmid: 16341240
references.citation: Cancer Chemother Pharmacol. 1992;30(1):7-11
references.pmid: 1375134
references.citation: Cancer Res. 2001 Feb 15;61(4):1327-33
references.pmid: 11245429
references.citation: Nat Genet. 1999 Jan;21(1):103-7
references.pmid: 9916800
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4
references.pmid: 7937876
references.citation: Cancer Cell. 2004 Aug;6(2):151-8
references.pmid: 15324698
references.citation: Oncogene. 2001 Nov 22;20(53):7787-96
references.pmid: 11753657
references.citation: Blood. 2006 Feb 1;107(3):1174-7
references.pmid: 16239434
references.citation: Cell. 2007 Feb 23;128(4):683-92
references.pmid: 17320506
references.citation: Clin Cancer Res. 2002 Mar;8(3):718-28
references.pmid: 11895901
references.citation: Proc Natl Acad Sci U S A. 1984 Nov;81(22):6993-7
references.pmid: 6209710
references.citation: Int J Cancer. 2008 Jul 1;123(1):8-13
references.pmid: 18425818
references.citation: Cancer J. 2007 Mar-Apr;13(2):105-13
references.pmid: 17476138
references.citation: Cancer J. 2007 Mar-Apr;13(2):80-3
references.pmid: 17476134
references.citation: Mol Cell Biol. 2008 May;28(10):3219-35
references.pmid: 18332107
references.citation: Int J Cancer. 2003 Jan 10;103(2):177-84
references.pmid: 12455031
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5777-85
references.pmid: 17020984
references.citation: Mol Cell Biol. 2000 Jul;20(14):5276-84
references.pmid: 10866684
references.citation: Cancer Cell. 2004 Apr;5(4):341-51
references.pmid: 15093541
references.citation: Ann N Y Acad Sci. 2005 Nov;1058:246-54
references.pmid: 16394141
references.citation: Br J Cancer. 2000 Sep;83(6):817-25
references.pmid: 10952788
references.citation: Oncogene. 1994 Nov;9(11):3375-8
references.pmid: 7936665
references.citation: J Biol Chem. 1977 Sep 25;252(18):6438-42
references.pmid: 893418
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):826-32
references.pmid: 18245545
references.citation: Mol Cell Biol. 2004 Feb;24(3):1270-8
references.pmid: 14729971